Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Gains from Sales and Divestitures (2020 - 2023)

Historic Gains from Sales and Divestitures for Serina Therapeutics (SER) over the last 4 years, with Q3 2023 value amounting to $3000.0.

  • Serina Therapeutics' Gains from Sales and Divestitures fell 7000.0% to $3000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $3000.0, marking a year-over-year decrease of 7000.0%. This contributed to the annual value of $13000.0 for FY2022, which is 833.33% up from last year.
  • Per Serina Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $3000.0 for Q3 2023, which was down 7000.0% from $3000.0 recorded in Q2 2023.
  • Serina Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $22000.0 during Q4 2020, with a 5-year trough of $3000.0 in Q1 2020.
  • Its 4-year average for Gains from Sales and Divestitures is $9181.8, with a median of $7000.0 in 2022.
  • Per our database at Business Quant, Serina Therapeutics' Gains from Sales and Divestitures soared by 1666.67% in 2022 and then crashed by 7000.0% in 2023.
  • Over the past 4 years, Serina Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $22000.0 in 2020, then crashed by 45.45% to $12000.0 in 2021, then increased by 8.33% to $13000.0 in 2022, then plummeted by 76.92% to $3000.0 in 2023.
  • Its last three reported values are $3000.0 in Q3 2023, $3000.0 for Q2 2023, and $3000.0 during Q1 2023.